Innovstone Therapeutics Limited
Clinical trials sponsored by Innovstone Therapeutics Limited, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New inhaled drug SYH2059 begins first human safety tests Results expected Dec 2026 (estimated)
- Could a new pill quiet the mind? early trial puts SYH2056 to the test Results expected Jan 2027 (estimated)
- New experimental drug SYH2072 tested in humans for the first time Results expected Feb 2027 (estimated)
-
New pill aims to slow lung scarring in IPF patients
Disease control Not yet recruitingThis study tests an experimental tablet called SYH2059 in 156 adults with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing harder. Participants will receive either the drug or a placebo to see if it can slow the decline in lung function. The…
Phase 2 • Sponsor: InnovStone Therapeutics Limited • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Could a new pill quiet the mind? early trial puts SYH2056 to the test
Knowledge-focused Not yet recruitingThis early-stage trial is testing an experimental oral drug called SYH2056 in healthy adults aged 18 to 55. The main goals are to see how safe and tolerable the drug is, how it moves through the body, and whether taking it with food changes its effects. Participants receive eithe…
Phase 1 • Sponsor: InnovStone Therapeutics Limited • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC
-
New inhaled drug SYH2059 begins first human safety tests
Knowledge-focused Not yet recruitingThis Phase 1 trial will test the safety and tolerability of an inhaled drug called SYH2059 in 84 healthy adults. Participants will receive either single or multiple doses of the drug or a placebo. The study aims to understand how the body processes the drug and whether it causes …
Phase 1 • Sponsor: InnovStone Therapeutics Limited • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC